Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06505603 · ClinicalTrials.gov registry record
PiMZ Longitudinal Cohort (PiMZ Logic)
A clinical trial of Alpha-1 Antitrypsin Deficiency and Emphysema or COPD, sponsored by Columbia University.
- Recruiting
- Registry status
- 80
- Enrollment target
- 5
- Study locations
NCT06505603: Recruiting study of Alpha-1 Antitrypsin Deficiency and Emphysema or COPD, sponsored by Columbia University.
NCT06505603 is a study of Alpha-1 Antitrypsin Deficiency and Emphysema or COPD that is actively recruiting participants, run by Columbia University. The registered enrollment target is 80 participants, below the 2,338-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06505603, a study of Alpha-1 Antitrypsin Deficiency and Emphysema or COPD, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 5
- Study locations
Study Summary
Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. Presentations are variable in the heterozygous population, the most predominant genotype being PiMZ. The purpose of this study in PiMZ heterozygous patients is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers pertinent to the PiMZ patient that can be used in interventional trials since lung function changes do not typically inform disease progression in AATD.
Primary Outcome
Change in lung density over three years determined by using the 15th percentile point (PERC-15) of Hounsfield units in inspiratory high resolution CT scans.
Conditions Studied
Study Locations (5)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California- Los Angeles - Los Angeles
Colorado
- National Jewish Health - Denver
Illinois
- University of Chicago - Chicago
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2029-02 |
What NCT06505603 shows while recruiting
NCT06505603 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 2,338-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT06505603 lists 5 locations in 5 states (Alabama, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT06505603 about?
NCT06505603 is a clinical study titled "PiMZ Longitudinal Cohort (PiMZ Logic)". Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. Presentations are variable in the heterozygous population, the most predominant genotype being PiMZ. The purpose of this study in PiMZ heterozygous patients is to examine the density of the lung as...
What is the current status of trial NCT06505603?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2025-05-30. Estimated completion is 2029-02.
What conditions does trial NCT06505603 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency, Emphysema or COPD.
Who is sponsoring clinical trial NCT06505603?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06505603 being conducted?
This trial has 5 study locations across Alabama, California, Colorado, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06505603's enrollment target sits among peer trials
80 12th of 24 higher than 13 of 24 other Alpha-1 Antitrypsin Deficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alpha-1 Antitrypsin Deficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
-
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
RECRUITING
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
Alpha-1 Research Registry
RECRUITING
-
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI